started · updated
Telix Pharmaceuticals to acquire ITM in deal worth up to $2.35 billion
Telix Pharmaceuticals Ltd. has entered into an agreement to acquire ITM Isotope Technologies Munich SE in a deal valued at up to US$2.35 billion. The acquisition aims to strengthen Telix’s position in the global radiopharmaceutical and radioisotope markets by integrating ITM’s manufacturing and distribution capabilities.
Under the terms of the agreement, Telix will acquire 100% of ITM’s shares for an upfront payment of US$1.65 billion on a cash-free, debt-free basis. The deal includes up to US$700 million in contingent consideration tied to regulatory approvals and sales milestones for ITM-11, a therapeutic candidate for gastroenteropancreatic neuroendocrine tumors.
ITM is a major producer of medical radioisotopes, including lutetium-177, actinium-225, and terbium-161, with a distribution network spanning over 65 countries. ITM reported annual revenue of US$273 million in 2025. Following the transaction, existing Telix shareholders are expected to hold approximately 76.3% of the combined company. The deal is subject to shareholder approval and regulatory clearances, with an expected close by the end of fiscal 2026.
Entities
ITM Isotope Technologies Munich SE · Indianapolis · Melbourne · Munich · Telix Pharmaceuticals Ltd.
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] The transaction is valued at up to US$2.35 billion. www.finanzen.at · www.finanzen.ch · www.globenewswire.com
- [○ 1 SOURCE] Following the transaction, existing Telix shareholders are expected to own approximately 76.3% of the combined company. www.finanzen.at
- [● 3 SOURCES] Telix will acquire 100% of ITM's shares for an upfront payment of US$1.65 billion on a cash-free, debt-free basis. www.finanzen.at · www.finanzen.ch · www.globenewswire.com
- [● 2 SOURCES] The transaction is expected to close by the end of fiscal 2026. www.finanzen.at · www.finanzen.ch
- [○ 1 SOURCE] ITM produces therapeutic radioisotopes including lutetium-177, actinium-225, and terbium-161. www.globenewswire.com
- [● 3 SOURCES] Telix Pharmaceuticals Ltd. has signed an agreement to acquire ITM Isotope Technologies Munich SE. www.finanzen.at · www.finanzen.ch · www.globenewswire.com
- [● 3 SOURCES] The deal includes up to US$700 million in contingent consideration based on regulatory approvals and sales milestones for ITM-11. www.finanzen.at · www.finanzen.ch · www.globenewswire.com
- [● 2 SOURCES] ITM reported annual revenue of US$273 million in 2025. www.finanzen.at · www.finanzen.ch